JP6389125B2 - 赤血球の処理法 - Google Patents

赤血球の処理法 Download PDF

Info

Publication number
JP6389125B2
JP6389125B2 JP2014541155A JP2014541155A JP6389125B2 JP 6389125 B2 JP6389125 B2 JP 6389125B2 JP 2014541155 A JP2014541155 A JP 2014541155A JP 2014541155 A JP2014541155 A JP 2014541155A JP 6389125 B2 JP6389125 B2 JP 6389125B2
Authority
JP
Japan
Prior art keywords
nitric oxide
red blood
transfusion
stored
therapeutic gas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014541155A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014532764A (ja
JP2014532764A5 (enExample
Inventor
ウォーレン エム． ザポル
ウォーレン エム． ザポル
ビンラン ユ
ビンラン ユ
Original Assignee
ザ ジェネラル ホスピタル コーポレイション
ザ ジェネラル ホスピタル コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ジェネラル ホスピタル コーポレイション, ザ ジェネラル ホスピタル コーポレイション filed Critical ザ ジェネラル ホスピタル コーポレイション
Publication of JP2014532764A publication Critical patent/JP2014532764A/ja
Publication of JP2014532764A5 publication Critical patent/JP2014532764A5/ja
Application granted granted Critical
Publication of JP6389125B2 publication Critical patent/JP6389125B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/02—Blood transfusion apparatus
    • A61M1/0281—Apparatus for treatment of blood or blood constituents prior to transfusion, e.g. washing, filtering or thawing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/02—Gases
    • A61M2202/0266—Nitrogen (N)
    • A61M2202/0275—Nitric oxide [NO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0413—Blood
    • A61M2202/0429—Red blood cells; Erythrocytes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2014541155A 2011-11-07 2012-11-06 赤血球の処理法 Active JP6389125B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161556661P 2011-11-07 2011-11-07
US61/556,661 2011-11-07
PCT/US2012/063690 WO2013070592A1 (en) 2011-11-07 2012-11-06 Treatment of red blood cells

Publications (3)

Publication Number Publication Date
JP2014532764A JP2014532764A (ja) 2014-12-08
JP2014532764A5 JP2014532764A5 (enExample) 2015-12-24
JP6389125B2 true JP6389125B2 (ja) 2018-09-12

Family

ID=48290479

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014541155A Active JP6389125B2 (ja) 2011-11-07 2012-11-06 赤血球の処理法

Country Status (6)

Country Link
US (1) US9572833B2 (enExample)
EP (1) EP2776047A4 (enExample)
JP (1) JP6389125B2 (enExample)
CN (1) CN104159591A (enExample)
HK (1) HK1200355A1 (enExample)
WO (1) WO2013070592A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12529737B2 (en) * 2019-03-25 2026-01-20 Ronald Day Systems and methods for using improved contrast agent in performing and MRI
WO2021015235A1 (ja) * 2019-07-22 2021-01-28 学校法人北里研究所 透析装置
CN111919835B (zh) * 2020-08-06 2022-02-08 温州医科大学 维持红细胞活性的保存液
EP4123303A1 (en) * 2021-07-20 2023-01-25 German Red Cross Blood Donor Service Baden-Württemberg-Hessen gGmbH Non-invasive method for predicting the hemoglobin and iron content in prbc units
EP4633693A1 (en) 2022-12-16 2025-10-22 Fresenius Medical Care Holdings, Inc. Systems and methods for using nitric oxide in dialysis
WO2025212681A1 (en) * 2024-04-01 2025-10-09 Ohio State Innovation Foundation Compositions, kits, and methods for the preservation of blood products

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5396882A (en) 1992-03-11 1995-03-14 The General Hospital Corporation Generation of nitric oxide from air for medical uses
DE69127756T2 (de) 1990-12-05 1998-02-05 The General Hospital Corp., Charlestown, Mass. Verwendung von no zur behandlung oder prävention der bronchokonstriktion
US5570683A (en) * 1990-12-05 1996-11-05 The General Hospital Corporation Methods and devices for treating pulmonary vasoconstriction and asthma
US5536241A (en) 1990-12-05 1996-07-16 The General Hospital Corporation Methods and devices for relaxing smooth muscle contractions
US5296466A (en) 1992-02-19 1994-03-22 Board Of Regents, The University Of Texas System Inhibition of nitric oxide-mediated hypotension and septic shock with iron-containing hemoprotein
US5423738A (en) * 1992-03-13 1995-06-13 Robinson; Thomas C. Blood pumping and processing system
DE59409834D1 (de) 1993-04-17 2001-09-27 Messer Griesheim Austria Ges M Gerät zur kontrollierten Zudosierung von NO zur Atemluft von Patienten
TW381022B (en) 1993-08-16 2000-02-01 Hsia Jen Chang Compositions and methods utilizing nitroxides to avoid oxygen toxicity, particularly in stabilized, polymerized, conjugated, or encapsulated hemoglobin used as a red cell substitute
GB9320978D0 (en) 1993-10-12 1993-12-01 Higenbottam Timohy W Nitric oxide treatment
SE9303486L (sv) 1993-10-22 1995-04-23 Siemens Elema Ab Metod vid bestämning av den funktionella residualkapaciteten för lungor samt en ventilatoranordning för bestämning av den funktionella residualkapaciteten
US5558083A (en) 1993-11-22 1996-09-24 Ohmeda Inc. Nitric oxide delivery system
SE503876C2 (sv) 1994-11-30 1996-09-23 Kjell Alving Detektion av inflammatoriska tillstånd i tarmkanalen genom att mäta kväveoxidhalten i ett prov taget ur tarmlumen
US6063407A (en) 1995-02-16 2000-05-16 The General Hospital Corporation Treatment of vascular thrombosis and restenosis with inhaled nitric oxide
US5823180A (en) 1995-04-03 1998-10-20 The General Hospital Corporation Methods for treating pulmonary vasoconstriction and asthma
US6627738B2 (en) * 1995-09-15 2003-09-30 Duke University No-modified hemoglobins and uses therefor
JP2000510448A (ja) * 1996-04-05 2000-08-15 ザ ジェネラル ホスピタル コーポレーション 異常ヘモグロビン症の治療
WO1998008500A1 (en) 1996-08-26 1998-03-05 Board Of Regents, The University Of Texas System Hypertonic arginine compositions and methods
CA2278784A1 (en) * 1997-02-06 1998-08-13 Jonathan S. Stamler No-modified hemoglobins and uses therefor
WO1998050430A2 (en) * 1997-05-02 1998-11-12 Somatogen, Inc. Hemoglobin mutants with increased soluble expression and/or reduced nitric oxide scavenging
US5900402A (en) 1997-05-29 1999-05-04 Enzon, Inc. Method of reducing side effects associated with administration of oxygen-carrying proteins
US6087087A (en) * 1997-07-03 2000-07-11 Takashi Yonetani Treatment of hemoglobin with nitric oxide
US6656452B1 (en) 1997-10-21 2003-12-02 The General Hospital Corporation Use of inhaled NO as anti-inflammatory agent
US6089229A (en) 1998-05-26 2000-07-18 Datex-Ohmeda, Inc. High concentration no pulse delivery device
US6139506A (en) 1999-01-29 2000-10-31 Instrumentarium Oy Method for measuring pulmonary functional residual capacity
IL147112A0 (en) * 1999-06-14 2002-08-14 Ford Henry Health System Nitric oxide donors for inducing neurogenesis
EP1204870B1 (en) * 1999-08-02 2010-01-20 Duke University Method for determining physiological effects of hemoglobin
US6894150B1 (en) 1999-10-01 2005-05-17 Ross Walden Tye Non-pyrogenic, endotoxin-free, stroma-free tetrameric hemoglobin
US7516742B2 (en) 1999-11-24 2009-04-14 Cardinal Health 207, Inc. Method and apparatus for delivery of inhaled nitric oxide to spontaneous-breathing and mechanically-ventilated patients with intermittent dosing
US6601580B1 (en) 2000-06-28 2003-08-05 The General Hospital Corporation Enhancing therapeutic effectiveness of nitric oxide inhalation
US6811778B2 (en) 2001-09-10 2004-11-02 Biopure Corporation Method for improving oxygen transport by stored red blood cells
US20030153491A1 (en) * 2002-01-11 2003-08-14 Winslow Robert M. Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
AU2003210952A1 (en) * 2002-02-08 2003-09-02 Gambro, Inc. Nitric oxide in a pathogen inactivation process
EP1514103A4 (en) * 2002-05-29 2006-05-24 Univ Duke MEASUREMENT OF NITROGEN MONOXIDE IN HEMOTOXIC GASES, AND TREATMENT BASED ON THIS MEASURE
WO2005004884A2 (en) 2003-07-09 2005-01-20 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Use of nitrite salts for the treatment of cardiovascular conditions
WO2005025511A2 (en) 2003-09-10 2005-03-24 Cedars-Sinai Medical Center Potassium channel mediated delivery of agents through the blood-brain barrier
US7485324B2 (en) * 2003-09-29 2009-02-03 Pulmonox Technologies Corporation Use of exogenous gaseous nitric oxide in the treatment and disinfection of biofilms
WO2005077005A2 (en) 2004-02-04 2005-08-25 The General Hospital Corporation Enhancing the effectiveness of an inhaled therapeutic gas
US20050234030A1 (en) 2004-04-20 2005-10-20 Wilmin Bartolini Modulators of CRTH2, COX-2 and FAAH
US7362274B1 (en) 2004-07-09 2008-04-22 Huan-Cheng Lien Coupled feed-in butterfly shaped left/right hand circularly polarized microstrip antenna
EP1799210A1 (en) 2004-10-05 2007-06-27 Bayer HealthCare AG A guanylate cyclase stimulator and nitric oxide for treating bronchoconstriction and pulmonary vasconstriction
US7530353B2 (en) 2005-09-21 2009-05-12 The General Electric Company Apparatus and method for determining and displaying functional residual capacity data and related parameters of ventilated patients
WO2007076318A2 (en) 2005-12-21 2007-07-05 Smithkline Beecham Corporation Camphor-derived cxcr3 antagonists
KR20090087900A (ko) * 2006-11-07 2009-08-18 더 제너럴 하스피탈 코포레이션 혈관작용성 산소운반체에 의해 유도되는 혈관수축의 감소
WO2009038796A1 (en) * 2007-09-20 2009-03-26 Wake Forest University Health Sciences Methods of treatment for hemolysis
DK3266463T3 (da) * 2009-06-09 2024-01-08 Prolong Pharmaceuticals Llc Hæmoglobinsammensætninger

Also Published As

Publication number Publication date
EP2776047A1 (en) 2014-09-17
JP2014532764A (ja) 2014-12-08
US20140286921A1 (en) 2014-09-25
WO2013070592A1 (en) 2013-05-16
CN104159591A (zh) 2014-11-19
HK1200355A1 (en) 2015-08-07
EP2776047A4 (en) 2015-07-22
US9572833B2 (en) 2017-02-21

Similar Documents

Publication Publication Date Title
US9572833B2 (en) Treatment of red blood cells
JP2010538973A (ja) 選択的細胞吸着除去装置およびその関連方法
CN111406737B (zh) 用于器官持续维持的成分、装置和方法
Lei et al. Inhaled nitric oxide attenuates the adverse effects of transfusing stored syngeneic erythrocytes in mice with endothelial dysfunction after hemorrhagic shock
US12582674B2 (en) Methods and treatment of trauma
JP2022093350A (ja) 輸血を必要とする患者集団における有害事象を管理するための方法
US20230248767A1 (en) Methods for Managing Adverse Events in Patients with Inflammation
Nagababu et al. The impact of surgery and stored red blood cell transfusions on nitric oxide homeostasis
ES2796962T3 (es) Filtro de sangre
O'Brien et al. The use of glycerolized frozen blood in vascular surgery and extracorporeal circulation
JP2005527834A (ja) 血液ガス中の一酸化窒素の測定およびそれに基づく処置
EP4590312A1 (en) Oxygen reduced blood for use in the treatment of traumatic brain injury accompanied by hemorrhagic shock
Wang Molecular mechanisms of surgery associated acute kidney injury (AKI) by blood degradation products in experimental mouse models
Williams Reducing the Dependence on Blood with Hemoglobin Based Oxygen Carriers
Hanssen et al. NO-Ventilation Attenuates the Deleterious Effects of Cell-Free Hemoglobin on Microcirculatory Blood Flow and Injury in the Kidney
Nicol et al. When to give blood
Zambelli A Comparison of the Effects of Packed Red Blood Cell Transfusion and Oxyglobin® in Canine Babesiosis
Kohn Use of oxyglobin in cats.
McConachie Anaemia and blood transfusion

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140922

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151102

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151102

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160822

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170412

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170711

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171012

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180726

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180802

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180816

R150 Certificate of patent or registration of utility model

Ref document number: 6389125

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250